Controlled release of berberine modulates the wound microbiome to accelerate wound healing.
Xu Z, Zhang L, Guo J, et al. Controlled release of berberine modulates the wound microbiome to accelerate wound healing. Asian J Pharm Sci 2026.
Study type: Animal (wound model with microbiome sequencing) · Added to this library August 23, 2026
What the researchers did
Berberine delivered from sustained-release scaffolds into healing wounds.
What they found
Sustained release healed best; sequencing showed berberine reshaped the wound's bacterial community and modulated immune signalling (CXCL10/IFN-α).
Why it matters
An ointment IS a sustained-release vehicle — the traditional sesame-oil/beeswax base does by craft what this 2026 paper does by engineering.
Relates to the patterns: Damp-Heat · Heat-Toxin
This summary is educational and does not replace care from your child's pediatrician. Evidence tiers matter: a finding in cells or animals is a reason a treatment could work, not proof that it does.
More in Huang Lian Gao
Huanglian ointment alleviates eczema by maintaining the balance of c-Jun and JunB and inhibiting AGE-RAGE-mediated pro-inflammation signaling pathway.
Wang S, Wang Y, Han B, Chen Y, Bai X, Yu S, Liu M. Huanglian ointment alleviates eczema by maintaining the balance of c-Jun and JunB and inhibiting AGE-RAGE-mediated pro-inflammation signaling pathway. Phytomedicine 2022;105:154372.
Study type: Animal (Biostir-AD guinea pig) + in vitro (TNF-α/IFN-γ HaCaT) + network pharmacology
Found: 14 components by GC-MS; 78 eczema-intersecting targets (Jun family, inflammatory regulators, chemokines). In vivo: reduced lesions, restored histology, lowered TNF-α, IFN-γ, IL-6. In vitro: protected keratinocytes, suppressed TARC/MDC/RANTES. Mechanism: restored filaggrin via c-Jun/JunB balance; inhibited AGE-RAGE.
Why it matters: Huang Lian Gao is a barrier-repair agent as well as a heat-toxin antimicrobial — this supports its use on hot, inflamed Damp-Heat lesions, not only visibly infected ones.
Berberine Inhibits the Inflammatory Response Induced by Staphylococcus aureus Isolated from Atopic Eczema Patients via the TNF-α/Inflammation/RAGE Pathways.
Maskey AR, Kopulos D, Kwan M, et al. Berberine Inhibits the Inflammatory Response Induced by Staphylococcus aureus Isolated from Atopic Eczema Patients via the TNF-α/Inflammation/RAGE Pathways. Cells 2024;13(19).
Study type: In vitro + animal (keratinocyte/immune cell lines; S. aureus isolated from real eczema patients)
What: Exposed human skin cells to S. aureus strains taken from eczema patients, with and without berberine (the main active compound of Huang Lian).
Found: Berberine was bacteriostatic and suppressed TNF-α by more than 90% at 20 µg/mL, down-regulated inflammatory genes and reduced oxidative stress — through the same RAGE pathway the Huanglian-ointment study found independently in 2022.
Why it matters: "Resolve Toxin" is both halves at once — restrain the bacterium and switch off the skin's overreaction to it. Two labs, two years apart, found the same pathway.
A berberine-loaded hydrogel for the treatment of atopic dermatitis through antibacterial activity, inhibition of inflammation and modulation of oxidative stress.
Peng Z, Wei XY, Zeng X, et al. A berberine-loaded hydrogel for the treatment of atopic dermatitis through antibacterial activity, inhibition of inflammation and modulation of oxidative stress. Front Immunol 2026.
Study type: Animal (topical, AD mouse model) + in vitro
What: A modern topical berberine hydrogel applied to mice with eczema-like disease.
Found: Reduced redness, swelling and crusting; suppressed inflammatory markers; restored skin-barrier proteins, via PI3K/AKT/NF-κB.
Why it matters: A 2026 pharmaceutical formulation arriving at what Huang Lian Gao already is: topical berberine for inflamed, infection-prone eczema.
Berberine induces anti-atopic dermatitis effects through the downregulation of cutaneous EIF3F and MALT1 in NC/Nga mice.
Andoh T, Yoshihisa Y, Rehman MU, Tabuchi Y, Shimizu T. Berberine induces anti-atopic dermatitis effects through the downregulation of cutaneous EIF3F and MALT1 in NC/Nga mice. Biochem Pharmacol 2021;185:114429.
Study type: Animal (oral, NC/Nga AD mouse model)
What: Oral berberine in the standard Japanese eczema mouse model.
Found: Less scratching, lower skin symptom scores, fewer eosinophils and mast cells in skin; mechanism traced to mast-cell genes (EIF3F, MALT1).
Why it matters: Independent evidence that berberine quiets the mast-cell and itch machinery, not just bacteria.